The efficacy and safety of sirolimus‐based graft‐versus‐host disease prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation: a meta‐analysis of randomized controlled trials
- 9 April 2015
- journal article
- research article
- Published by Wiley in Transfusion
- Vol. 55 (9) , 2134-2141
Abstract
BACKGROUND: The efficacy and safety of sirolimus (SIR)‐based graft‐versus‐host disease (GVHD) prophylaxis in patients who were subjected to allogeneic hematopoietic stem cell transplantation (allo‐HSCT) remain to be clarified; this meta‐analysis was conducted to evaluate these factors.STUDY DESIGN AND METHODS: Data from original research were obtained from PubMed, Embase, and Cochrane central register of controlled trials databases. Randomized controlled trials (RCTs) evaluating the efficacy of SIR‐based prophylaxis in allo‐HSCT were included. The risk ratio (RR), with a 95% confidence interval (CI), was used to pool data. The random effects model was used, irrespective of the presence or absence of heterogeneity.RESULTS: Five RCTs were included in the meta‐analysis. SIR was observed to significantly decrease the incidence of Grade II to IV acute GVHD (aGVHD; RR, 0.65; 95% CI, 0.47‐0.89). However, the incidence of Grade III to IV aGVHD and chronic GVHD was not decreased (RR, 0.91; 95% CI, 0.59‐1.40; RR, 1.04; 95% CI, 0.88‐1.23, respectively). An analysis of the toxic effects of SIR revealed that SIR effected a significant increase in the incidence of sinusoidal obstructive syndrome (RR, 2.24; 95% CI, 1.26‐4.01), while that of thrombotic microangiopathy was not significantly increased (RR, 2.48; 95% CI, 0.87‐7.06). Moreover, SIR did not improve event‐free survival and overall survival (RR, 0.97; 95% CI, 0.85‐1.10; and RR, 0.92; 95% CI, 0.82‐1.02, respectively).CONCLUSION: This meta‐analysis indicated that the SIR‐based regimen is an effective and safe alternative prophylaxis strategy for GVHD.Keywords
Funding Information
- National Natural Science Foundation of China ((No. 81270642))
This publication has 31 references indexed in Scilit:
- Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoidsHaematologica, 2011
- A Phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graftversushost disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL)British Journal of Haematology, 2009
- Sirolimus, Tacrolimus, and Low-Dose Methotrexate as Graft-versus-Host Disease Prophylaxis in Related and Unrelated Donor Reduced-Intensity Conditioning Allogeneic Peripheral Blood Stem Cell TransplantationTransplantation and Cellular Therapy, 2008
- Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantationBlood, 2006
- Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 productionBlood, 2006
- Hematopoietic Stem-Cell TransplantationNew England Journal of Medicine, 2006
- Rapamycin (sirolimus) for treatment of chronic graft-versus-host diseaseTransplantation and Cellular Therapy, 2005
- Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantationBlood, 2003
- The rapamycin-sensitive signal transduction pathway as a target for cancer therapyOncogene, 2000
- Rapamune® (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progressionClinical Biochemistry, 1998